BIONTECH SE ADR
BIONTECH SE ADR
Acción · US09075V1026 · BNTX · A2PSR2 (XFRA)
Resumen Indicadores financieros
95,21 EUR
-0,56 % -0,54 EUR
Precio de cierre XFRA 06.06.2025: 96,45 EUR
Frankfurt (XNAS) · Precios actuales y gráficos en MoneyPeak
06.06.2025 22:29

Cotizaciones actuales de BIONTECH SE ADR

BolsaTickerMonedaÚltima operaciónPrecioVariación diaria
XNAS: NASDAQ
NASDAQ
BNTX
USD
06.06.2025 22:29
108,54 USD
110,15 USD
-1,46 %
XFRA: Frankfurt
Frankfurt
22UA.F
EUR
06.06.2025 17:13
96,45 EUR
97,75 EUR
-1,33 %

Rendimiento

Día Semana Mes 3 meses 6 meses 1 año 5 años
0,00 % 12,96 % 13,69 % -6,90 % -17,32 % 1,06 % 118,66 %

Perfil de la empresa para BIONTECH SE ADR Acción

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, a preclinical stage product for non-small cell lung cancer. It also develops neoantigen specific immunotherapies, such as Autogene cevumeran (BNT122), which is in Phase II clinical trial for first-line melanoma, as well as in Phase 1a/1b clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT153 to treat solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT221 for other cancers; and checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I/II clinical trial to treat solid tumors. Further, it develops BNT321, an IgG1 monoclonal antibody in Phase II clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate for solid tumors; prophylactic vaccine for COVID-19 and Influenza; and infectious disease immunotherapies and rare disease protein replacement therapies. The company has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd.; and Regeneron Pharmaceuticals, Inc. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

Fondos invertidos

Los siguientes fondos han invertido en: BIONTECH SE ADR invertido:

Fondo
iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)
Vol. en millones
862,43
Porcentaje (%)
2,02 %

Datos de la empresa

Nombre BIONTECH SE ADR
Empresa BioNTech SE
Símbolo BNTX
Sitio web https://www.biontech.de
Mercado principal XFRA Frankfurt
WKN A2PSR2
ISIN US09075V1026
Tipo de valor Acción
Sector Healthcare
Industria Biotechnology
CEO Dr. Ugur Sahin M.D.
Capitalización de mercado 21 Mrd.
País Alemania
Moneda EUR
Empleados 6,8 T
Dirección An der Goldgrube 12, 55131 Mainz
Fecha de OPV 2019-10-11

Símbolos de cotización

Nombre Símbolo
Frankfurt 22UA.F
NASDAQ BNTX
XETRA 22UA.DE

Otras acciones

Los inversores que tienen BIONTECH SE ADR también tienen las siguientes acciones en su cartera:
ALIBABA GR. SP.ADR 8
ALIBABA GR. SP.ADR 8 Acción
ALPHABET INC - CLASS A
ALPHABET INC - CLASS A Acción
AMAZON.CO INC
AMAZON.CO INC Acción
APPLE INC
APPLE INC Acción
EPIC Suisse AG
EPIC Suisse AG Acción
META PLATFORMS INC
META PLATFORMS INC Acción
MICROSOFT CORP
MICROSOFT CORP Acción
MSCI 18/27 REGS
MSCI 18/27 REGS Bono
NVIDIA CORP
NVIDIA CORP Acción
PAYPAL INC
PAYPAL INC Acción
SQUARE INC A
SQUARE INC A Acción
TENNANT CO       DL-,375
TENNANT CO DL-,375 Acción
TESLA INC
TESLA INC Acción
UFP TECHNOLOGIESLOGIES INC
UFP TECHNOLOGIESLOGIES INC Acción
La plataforma financiera MoneyPeak rastrea y analiza inversiones y carteras. Desde depósitos de valores hasta compras de criptomonedas.
Útil, simple y gratuito. Acciones, ETF, ETC, ETN, índices, fondos, bonos, certificados, divisas, opciones, derechos de suscripción.
Aviso legal Protección de datos Blog Comunidad Comentarios Changelog
Im App Store herunterladen Bei Google Play herunterladen
Todos los derechos reservados © LCP GmbH 2025